(Q50921097)

25 March 2018

title

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. (English)

1 reference

25 March 2018

0 references

7

Charles Erlichman

1 reference

25 March 2018

Michelle R. Mahoney

2

object named as

Michelle R Mahoney

1 reference

25 March 2018

author name string

Howard H Bailey

1

1 reference

25 March 2018

David S Ettinger

3

1 reference

25 March 2018

William J Maples

4

1 reference

25 March 2018

Paula M Fracasso

5

1 reference

25 March 2018

Anne M Traynor

6

1 reference

25 March 2018

Scott H Okuno

8

1 reference

25 March 2018

language of work or name

English

0 references

publication date

1 November 2006

1 reference

25 March 2018

published in

Cancer

1 reference

25 March 2018

volume

107

1 reference

25 March 2018

page(s)

2462-2467

1 reference

25 March 2018

issue

10

1 reference

25 March 2018

The inhibition of cell signaling pathways by antitumor ether lipids

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

A three-outcome design for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Phase II trial of gemcitabine in advanced sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22308

7 January 2021

Identifiers

DOI

10.1002/CNCR.22308

1 reference

25 March 2018

PubMed ID

17058289

1 reference

25 March 2018